Annals of Oncology Advance Access originally published online on September 15, 2006
Annals of Oncology 2006 17(12):1766-1771; doi:10.1093/annonc/mdl313
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 European Society for Medical Oncology
hematologic malignancies |
Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy
1 Cleveland Clinic Cancer Center Myeloma Research Program, Cleveland Clinic, Cleveland
2 Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland
3 Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland
4 Hematology and Medical Oncology, Sparrow Cancer Center, Lansing, Celgene Corporation, Summit, USA
Correspondence to: Dr M. A. Hussein, M.D., Director, Myeloma Research Program, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk R35, Cleveland, OH 44195, USA. Tel: +1(216) 445 6830; Fax: +1(216) 445 3434; E-mail: mashussein{at}runbox.us
Background: Lenalidomide is active and well tolerated in relapsed and refractory multiple myeloma. We conducted a phase I/II trial of the combination of lenalidomide and chemotherapy to evaluate the safety and efficacy of the combination.
Methods: The 62 patients enrolled received liposomal doxorubicin 40 mg/m2 i.v. and vincristine 2 mg i.v. on day 1, dexamethasone 40 mg p.o. on days 1–4 (DVd), and lenalidomide on days 1–21 in 28-day cycles. Primary end points were maximum tolerated dose (MTD) of lenalidomide with DVd chemotherapy and overall response rate (ORR) by Southwest Oncology Group criteria of the combination.
Findings: The median age was 62 years, 70% of patients were males and 65% had refractory multiple myeloma. The MTD of lenalidomide with DVd chemotherapy was 10 mg and the dose-limiting toxicity was non-neutropenic sepsis. After 7.5 months of median follow-up, the ORR of the combination was 75%, with 29% of patients achieving a complete or near complete remission. The median progression-free survival was 12 months, while the median overall survival has not yet been reached.
Interpretation: The combination of lenalidomide and DVd chemotherapy was well tolerated and resulted in high response rates in this mostly refractory patient population. Evaluation of this combination in newly diagnosed patients is warranted.
Key words: Multiple Myeloma, Refractory, Lenalidomide, reduced dose dexamethasone, Doxil
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Zangari, L. M. Fink, F. Elice, F. Zhan, D. M. Adcock, and G. J. Tricot Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents J. Clin. Oncol., October 10, 2009; 27(29): 4865 - 4873. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Knop, C. Gerecke, P. Liebisch, M. S. Topp, U. Platzbecker, O. Sezer, C. Vollmuth, K. Falk, A. Glasmacher, U. Maeder, et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom) Blood, April 30, 2009; 113(18): 4137 - 4143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Chanan-Khan and B. D. Cheson Lenalidomide for the Treatment of B-Cell Malignancies J. Clin. Oncol., March 20, 2008; 26(9): 1544 - 1552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. V. Rao Lenalidomide in the treatment of multiple myeloma Am. J. Health Syst. Pharm., September 1, 2007; 64(17): 1799 - 1807. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. G. Richardson, C. Mitsiades, R. Schlossman, N. Munshi, and K. Anderson New Drugs for Myeloma Oncologist, June 1, 2007; 12(6): 664 - 689. [Abstract] [Full Text] [PDF]
|
|